Aldeyra’s lead product candidate, reproxalap (formerly ADX 102 or NS-2), is a small molecule RASP (Reactive Aldehyde Species) inhibitor in Phase 3 clinical development for the treatment of dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson syndrome. NS-2 has been tested in a variety of in vitro and preclinical models, and has demonstrated the ability to trap free aldehydes, diminish inflammation, reduce healing time, protect key cellular constituents from aldehyde damage, and lower the potential for scarring or fibrosis. NS-2 has been tested in a variety of toxicity studies in animals and appears to be generally safe and well tolerated. NS-2 has an orphan drug status for the treatment of Sjogren-Larsson syndrome.